Latest news with #GenomicRevolutionETF
Yahoo
5 days ago
- Business
- Yahoo
Why Cathie Wood Is Loading Up on This Hot Growth Stock (And Should You?)
In a market dominated by headlines about artificial intelligence (AI), cloud computing, and digital platforms, it is easy to overlook some of the most transformative developments in the life sciences. Cathie Wood, CEO of ARK Invest and known for her bold bets on disruptive innovation, has her sights set on Illumina (ILMN), a company that connects science and technology. On July 22, Wood's ARK's Genomic Revolution ETF (ARKG) bought 31,265 shares of Illumina, amounting to nearly $2.98 million, bringing the total investment in the company to $32 million. It is the ETF's 15th largest holding, comprising 2.8% of the overall portfolio. More News from Barchart UnitedHealth Stock Spirals Lower Again. Don't Buy the Dip. This Self-Driving Car Stock Is Surging on a Major Nvidia Boost Auto Revenue Keeps Plunging at Tesla. Should You Buy the TSLA Stock Dip or Run Far Away? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Let's find out if investors should follow Wood's lead and buy Illumina stock here. A High-Conviction Bet on the Future of Medicine Valued at $16.6 billion, Illumina is a biotechnology company that specializes in genome sequencing, or the process of reading and analyzing DNA. It manufactures machines (sequencers), software, and chemical kits that are used to decode the genetic material (DNA) of humans, animals, plants, and bacteria. Illumina's technology is used in hospitals and clinics, by cancer researchers, pharmaceutical companies, agricultural scientists, academics, and research institutions, among others. Some of its products include the NovaSeq X Series, iScan System, iSeq 100 System, Illumina DNA Prep, Illumina Stranded mRNA Prep, and many others. Illumina's stock price has dropped significantly since its 2021 highs, falling from above $500 to around the $100-$120 range by mid-2025. Much of this decline can be attributed to a series of self-inflicted wounds, most notably its controversial acquisition of cancer detection company Grail. However, with the Grail divestment in 2024 and a new CEO, Jacob Thaysen, in charge, Illumina appears to be refocusing on its core business of making genome sequencing cheaper, faster, and more accessible. Why the Timing Matters Now Wood is known for buying when volatility is high, particularly when she believes the market has overcorrected due to near-term concerns. Following the Grail divestment, leadership change, and a multi-quarter slump in revenue growth, investor sentiment is bearish on Illumina stock, explaining the nearly 20% drop year-to-date. However, Wood saw this as an opportunity to stock up on this rising genomic star. Illumina's financial performance appears to be stabilizing. For a growth investor like Wood, who prefers to overlook short-term earnings volatility in favor of long-term potential, these improvements are a welcome sign that the company is on the right track. In the first quarter, while revenue growth dipped slightly by 1.4%, the company improved its margins and reduced unnecessary expenses. Illumina exceeded revenue expectations and reaffirmed full-year guidance. Adjusted gross margins increased to 67.4% as a result of improved manufacturing efficiency and lower R&D costs. Adjusted earnings per share fell to $0.97 from $0.98 in the prior year's quarter. Remaining performance obligations (RPO) totaled $891 million, of which Illumina expects to generate 83% in revenue over the next year. With a reasonable debt-equity ratio of 0.63x, Illumina's balance sheet is stable. The company also generated a positive free cash flow of $208 million during the quarter. Illumina will report its second-quarter earnings on July 31. Analysts expect revenue of $1.05 billion on earnings per share of $1.01. Analysts predict a 3% drop in revenue for the full year but earnings growth of 72.9% to $4.24 per share, with an additional 9.5% increase expected in 2026. Another factor that may have influenced ARK's decision to increase its stake in Illumina is valuation. The stock is currently trading at 22 times forward earnings for 2026 and three times forward sales. Illumina has the world's largest genomics dataset, giving the company a competitive advantage. Many of Illumina's future revenue streams, including large-scale population sequencing contracts and new clinical applications in oncology and rare diseases, are not fully priced into current projections. This reasonable valuation represents a buying opportunity for a growth stock with excellent long-term prospects. What Is Wall Street Saying About Illumina Stock? Overall, the consensus on Illumina stock is a 'Moderate Buy.' Of the 22 analysts covering the stock, nine recommend a 'Strong Buy,' one suggests a 'Moderate Buy,' nine rate it a 'Hold,' one says it is a 'Moderate Sell,' and two have given it a 'Strong Sell' rating. The stock is trading close to its average target price of $106.83. However, the high price estimate of $185 suggests a rally of over 76.8% from current levels. The Key Takeaway Wood's stake in Illumina is a calculated investment based on extensive research, long-term vision, and a firm belief in the power of genomics to transform healthcare. Now, with a lower cost structure, a clear path back to profit growth, and exciting new products on the market, Illumina is poised for a turnaround. For investors with patience and a long horizon, Illumina stock represents a one-of-a-kind opportunity to invest in genomic infrastructure. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Business Insider
11-07-2025
- Business
- Business Insider
Cathie Wood Makes $16M Robotics Bet, Trims Stake in COIN and HOOD Stocks
Popular investor Cathie Wood's ARK Invest made key portfolio moves on Thursday, July 10, with the spotlight on a major buy in the industrial automation space. As per ARK's daily trade disclosures, the largest transaction of the day was a $16 million-plus purchase in Teradyne (TER), a leading name in robotics testing systems. At the same time, Wood continued to offload shares of cryptocurrency exchange Coinbase (COIN) and trading platform Robinhood (HOOD). Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Wood Loads Up on Teradyne Stock On Thursday, ARK ETFs bought 179,242 shares of Teradyne, valued at $16.63 million. This marks ARK's most significant trade of the day. The buy was made through multiple ARK funds, including the flagship ARK Innovation ETF (ARKK). Teradyne is a major name in industrial automation and testing, a sector where Wood has been steadily building exposure amid rising interest in AI and robotics. In another smaller but notable buy, ARK added 16,277 shares of Tempus AI (TEM) across ARKK and ARK Genomic Revolution ETF (ARKG), totaling $950,739. This followed a larger $8.8 million purchase the previous day, signaling growing interest in AI-driven healthcare. What Is the Teradyne Stock Price Forecast for 2025? On TipRanks, Teradyne stock has a Moderate Buy consensus rating based on nine Buys, two Holds, and three Sell ratings. Also, the average TER price target of $95.85 implies a 2.81% downside potential from current levels. Year-to-date, TER stock has gained 21.47%. ARK Cuts Stakes in Coinbase and Robinhood At the same time, ARK trimmed several tech holdings. Most notably, the firm sold 16,627 shares of Coinbase, worth $6.21 million, continuing a recent pattern of crypto pullbacks. The transaction follows two sizable Coinbase sales in late June—33,363 shares on June 27 and 124,892 shares on June 30—as ARK took profits during a sharp rally in the stock. Meanwhile, the firm also sold 58,504 shares of Robinhood for $5.53 million. This comes amid a broader move by ARK to reduce its exposure to consumer trading platforms. Turning to Wall Street, Coinbase stock scores a Moderate Buy consensus rating, with the average COIN stock price target of $307.93 indicating a 20.83% possible decline from current levels. Meanwhile, Robinhood also earns a Moderate Buy consensus rating, with the average HOOD stock price target reflecting a 19.10% downside risk. Notably, COIN is up 56.65% year-to-date, while HOOD has surged 165% over the same period.
Yahoo
10-07-2025
- Business
- Yahoo
Cathie Wood's ARK Loads Up on Tempus AI, Cuts Roku and Block
July 10 - Cathie Wood's ARK Invest purchased 150,563 shares of Tempus AI (NASDAQ:TEM), worth about $8.8 million, according to a Wednesday regulatory filing with the SEC. The bulk of the buy flowed through the ARK Innovation ETF (ARKK), with the remainder acquired via the ARK Genomic Revolution ETF (ARKG). Tempus AI applies artificial intelligence to clinical decision?making, a focus area for Wood's disruptive?tech strategy. Warning! GuruFocus has detected 5 Warning Signs with TEM. At the same time, ARK trimmed its position in Roku (NASDAQ:ROKU), selling 50,823 shares, roughly $4.5 million, also via ARKK. This marks a second consecutive day of reductions in the streaming platform stock. The fund likewise pared back exposure to Block, offloading 56,503 shares worth about $6.5 million, as part of a broader pullback from fintech names. These moves illustrate ARK's ongoing pivot toward AI health plays and away from streaming and payments. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
10-07-2025
- Business
- Business Insider
Cathie Wood Makes Her Largest Trade of the Day in This AI Stock, 7/10/2025
Popular investor Cathie Wood's ARK Invest made key portfolio moves on Wednesday, July 9, with the spotlight on a major buy in the AI healthcare space. As per ARK's daily trade disclosures, the largest transaction of the day was a fresh purchase in Tempus AI (TEM). At the same time, the fund continued to trim its holdings in streaming platform Roku (ROKU) and Block (XYZ), a digital payments company formerly known as Square. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Wood Loads Up on Tempus AI On Wednesday, Cathie Wood's ARK Invest made its largest trade of the day by purchasing 150,563 shares of Tempus AI, valued at around $8.8 million. The bulk of the buy came through the ARK Innovation ETF (ARKK), with additional shares acquired via the ARK Genomic Revolution ETF (ARKG). Tempus AI, which applies AI to improve clinical decisions in healthcare, continues to attract interest from Cathie Wood as part of her focus on disruptive technologies. Wall Street's Take on TEM On TipRanks, Tempus AI stock has a Moderate Buy consensus rating based on five Buy and three Hold ratings. Also, the average TEM price target of $68.86 implies a 17.89% upside potential from current levels. Year-to-date, TEM stock has gained 73%. Wood Trims Holdings in ROKU and BLOCK Stocks ARK continues to trim its position in Roku stock. On Wednesday, it sold 50,823 shares of Roku, totaling nearly $4.5 million, through ARKK. This marks a second straight day of cuts in Roku, hinting at a shift away from streaming-related stocks. Just yesterday, ARK trimmed its position in Roku, selling 20,813 shares worth about $1.83 million. Meanwhile, the firm also sold 56,503 shares of Block for more than $6.5 million. This comes amid a broader move by ARK to reduce its fintech exposure. Turning to Wall Street, Roku stock scores a Moderate Buy consensus rating, with the average Roku stock price target of $91.56 indicating a 3.31% possible decline from current levels. Meanwhile, XYZ also earns a Moderate Buy consensus rating, with the average Block stock price target reflecting a 1.55% downside risk. Notably, Roku has risen 19% so far this year, while Block is down 19%.
Yahoo
26-02-2025
- Business
- Yahoo
Ark Invest Buys the Dip as Cathie Wood Snaps Up Tempus AI Shares
Feb 26 - Cathie Wood and Ark Invest moved to acquire Transfus AI (TEM, Financial) shares after its share price dropped by 1.5%. Wood's team reacted to Tempus AI's earnings report disappointment by purchasing the healthcare technology firm's shares at reduced values. Ark Invest demonstrates its belief in TEM through this recent capital acquisition after observing short-term market fluctuations. Warning! GuruFocus has detected 2 Warning Sign with AMZN. Two investment funds managed by Ark Invest, named the Ark Innovation ETF (ARKK, Financial) and the ARK Genomic Revolution ETF (ARKG, Financial), completed 445,958 stock purchases. ARKK purchased 367388 shares alongside 78570 additional shares acquired by ARKG during the investments. The Tempus Systems portfolio within ARKK holds an 8th position with a 4.52% weighting amounting to AU$275.4 million market value on Wednesday. holds the fourth-largest position in the portfolio of ARKG, comprising 7.50% of its assets and a market worth of AU$90.8 million. The major Wall Street proponent of Tempus AI remains Wood, who continues to support the company through her substantial fund allocations in the market. Ark Invest demonstrates its investment approach for the healthcare technology market through strategic transactions, which indicates Ark Invest's method of acquiring market opportunities when prices dip for long-term growth in healthcare technology. Numerous investors now interpret TEMPUS AI's major buy-in as an optimistic indicator because market trends show promising results for the business. Analysts remain cautiously optimistic ahead. This article first appeared on GuruFocus. Sign in to access your portfolio
